1. The effects of mosaicism on biological and clinical markers of Alzheimer's disease in adults with Down syndromeResearch in context
- Author
-
Laura Xicota, Lam-Ha T. Dang, Alice Lee, Sharon Krinsky-McHale, Deborah Pang, Lisa Melilli, Sid O'Bryant, Rachel L. Henson, Charles Laymon, Florence Lai, H. Diana Rosas, Beau Ances, Ira Lott, Christy Hom, Bradley Christian, Sigan Hartley, Shahid Zaman, Elizabeth Head, Mark Mapstone, Zhezhen Jin, Wayne Silverman, Nicole Schupf, Benjamin Handen, Joseph H. Lee, Howard J. Aizenstein, Beau M. Ances, Howard F. Andrews, Karen Bell, Rasmus Birn, Adam M. Brickman, Peter Bulova, Amrita Cheema, Kewei Chen, Bradley T. Christian, Isabel Clare, Lorraine Clark, Ann D. Cohen, John N. Constantino, Eric W. Doran, Anne Fagan, Eleanor Feingold, Tatiana M. Foroud, Benjamin L. Handen, Jordan Harp, Sigan L. Hartley, Rachel Henson, Lawrence Honig, Milos D. Ikonomovic, Sterling C. Johnson, Courtney Jordan, M.Ilyas Kamboh, David Keator, William E. Klunk, Julia K. Kofler, William Charles Kreisl, Sharon J. Krinsky-McHale, Patrick Lao, Ira T. Lott, Victoria Lupson, Chester A. Mathis, Davneet Singh Minhas, Neelesh Nadkarni, Sid O’Bryant, Melisa Parisi, Melissa Pettersen, Julie C. Price, Margaret Pulsifer, Michael S. Rafii, Eric Reiman, Batool Rizvi, Laurie Ryan, Frederick Schmitt, Wayne P. Silverman, Dana L. Tudorascu, Rameshwari Tumuluru, Benjamin Tycko, Badri Varadarajan, Desiree A. White, Michael A. Yassa, and Fan Zhang
- Subjects
Down syndrome ,Mosaicism ,Alzheimer's disease ,Plasma biomarkers ,CSF ,PET ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Individuals with Down syndrome (DS) are at high risk of early-onset Alzheimer's disease (AD); yet, some 20 percent do not develop any signs of dementia until after 65 years or in their lifetime. Mosaicism could contribute to this phenotypic variation, where some disomic cells could lead to lower levels of gene products from chromosome 21. Methods: We examined longitudinal neuropsychological and biomarker data from two large studies of DS: the Alzheimer Biomarker Consortium–Down syndrome study (ABC-DS) (n = 357); and a legacy study (n = 468). We assessed mosaicism using karyotyping or GWAS data. Participants had data on plasma AD biomarkers (Aβ40, Aβ42, tau, and NfL) and longitudinal cognitive measures. A subset had cerebrospinal fluid biomarkers (Aβ40, Aβ42, tau, ptau181, and NfL) and amyloid and tau PET data. Findings: For both cohorts, the prevalence of mosaicism was
- Published
- 2024
- Full Text
- View/download PDF